Clinical Trial Update: FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sequencing of FOLFOX chemotherapy with Durvalumab (MEDI4736) and Bevacizumab, followed by stereotactic body radiotherapy, in potentiall…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Durvalumab (durvalumab)
• FOLFOX chemotherapy regimen (FOLFOX regimen (folinic acid, 5-fluorouracil, oxaliplatin))

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Hepatocellular Carcinoma (HCC) | Phase 2 | Status: NOT_YET_RECRUITING